Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Restarting breast cancer screening after COVID-19 disruption not so simple

Key clinical point: Strategies for restarting breast cancer screening after the COVID-19 disruption present a trade-off between health benefit and burden on screening programs.

Major finding: Relative to undisrupted screening, immediately catching up on missed screens post disruption yielded the smallest increase in breast cancer deaths (14 more deaths during 2020-2030) but required a doubling of program screening capacity in the latter half of 2020.

Study details: A modeling study that used simulations to compare four restart strategies against undisrupted screening.

Disclosures: The study did not have any specific funding. Ms. Kregting disclosed no conflicts of interest.

Citation:

Kregting L et al. EBCC-12 Virtual Conference, Abstract 24.